Aggrecan Antibodies to N-& C-Terminal Neoepitopes

Mar 08 , 2022

MD Bioproducts

Aggrecan, the major proteoglycan of articular cartilage, has received significant attention over the years as it is responsible for hydrating cartilage, giving it compressibility and resilience during joint loading, thereby playing a major role in the normal function of cartilage. The depletion of its glycosaminoglycan bearing aggrecan fragments has been found to be one of the earliest events in cartilage destruction. This cleavage is caused by proteases of two families: the matrix metalloprotease (MMP) family and the ADAMTS (a disintegrin-like and metalloprotease domain) family.

MD Bioproducts offers specific antibodies that recognize the termini created by these cleavage sites. These are commonly referred to as neoepitope antibodies and can be used to further understand the biochemistry of proteases and their effect on aggrecan.

Aggrecan degradation products containing this neoepitope are rapidly released from the tissue in model explant culture systems and are also present in synovial fluid with degenerative joint disease:

Aggrecan monoclonal antibody to N-terminal Neoepitope ARG
(Mouse, Clone BC-3)
Product 1042001
Aggrecan Antibody to N-Terminal Neoepitope ARG
(Clone BC-3), 0.1 mg/mL

Aggrecan monoclonal antibody to N-terminal Neoepitope DIPEN
(Mouse, Clone BC-4)
Product 1042002
Aggrecan Antibody to N-Terminal Neoepitope DIPEN
(Clone BC-4), 0.1 mg/mL

This aggrecan degradation product usually remains within the tissue still complexed to hyaluronan and link protein. Its release from the cartilage usually signals that there has been extensive catabolism of aggrecan, which allows large complexes containing this metabolite to be released from tissue:

Aggrecan monoclonal antibody to C-terminal Neoepitope NITEGE
(Mouse, Clone BC-13)
Product 1042003
Aggrecan Antibody to C-Terminal Neoepitope NITEGE
(Clone BC-13), 0.1 mg/mL

This fragment is rapidly released from tissue when MMP catabolism of aggrecan occurs and has been identified in synovial fluid samples with degenerative joint diseases:

Aggrecan monoclonal antibody to N-terminal Neoepitope FFGV
(Mouse, Clone BC-14)
Product 1042004
Aggrecan Antibody to N-Terminal Neoepitope FFGV
(Clone BC-14), 0.1 mg/mL

Aggrecanase Activity in Cartilage
Western Blot analysis using Aggrecan Antibody to N-Terminal Neoepitope ARG

(Clone BC-3) and Aggrecan Antibody to C-Terminal Neoepitope NITEGE (Clone BC-13) on media or 4M guanidine extracts from porcine articular cartilage explant cultures exposed for 7 days to: serum-free medium alone (Con) or serum-free media containing retinoic acid (RA), interleukin-1 (IL-1) or tumor necrosis factor-α (TNFα).

Selection of recent references to our Aggrecan Antibodies to N-& C-Terminal Neoepitopes:

Kang, D., Lee, J., Jung, J., Carlson, B. A., Chang, M. J., Chang, C. B., ... & Kim, J. H. (2022). Selenophosphate synthetase 1 deficiency exacerbates osteoarthritis by dysregulating redox homeostasis. Nature Communications, 13(1), 1-14.

Clement-Lacroix, P., Little, C. B., Smith, M. M., Cottereaux, C., Merciris, D., Meurisse, S., ... & Amantini, D. (2022). Pharmacological characterization of GLPG1972/S201086, a potent and selective small-molecule inhibitor of ADAMTS5. Osteoarthritis and Cartilage, 30(2), 291-301.

Brebion, F., Gosmini, R., Deprez, P., Varin, M., Peixoto, C., Alvey, L., ... & Amantini, D. (2021). Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis. Journal of Medicinal Chemistry, 64(6), 2937-2952.

Researchers who brought these antibodies also use:

Aggrecan , Cartilage , Inflammation Research

Older Post

Newer Post

Aggrecan Antibodies to N-& C-Terminal Neoepitopes

Shopping cart :